Amphastar Pharmaceuticals, Inc. (AMPH) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Amphastar Pharmaceuticals reported revenue of $719.9M, down 1.7% from $732.0M the year before. Net income was $98.1M (a 13.6% net margin), or $2.03 per diluted share. Gross margin was 49.5% and operating margin was 19.5%. Operating activities generated $156.1M of cash, leaving $121.2M of free cash flow. At fiscal year end, Amphastar Pharmaceuticals held $1.63B in total assets against $840.5M in total liabilities, including $170.2M of cash and equivalents.
Open the full interactive Amphastar Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Amphastar Pharmaceuticals Key Stats
| Share Price | $26.05 |
|---|---|
| Market Cap | $1.15B |
| P/E Ratio | 12.8 |
| Revenue YoY Growth | -1.7% |
| 52-Week Range | $16.87 – $29.40 |
| Shares Outstanding | 43.6 million (basic, 2026 Q2) |
Amphastar Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $349.8M | $437.8M | $499.0M | $644.4M | $732.0M | $719.9M |
| Gross Profit | $143.3M | $199.7M | $248.9M | $351.1M | $373.9M | $356.1M |
| Operating Income | $11.0M | $69.9M | $107.5M | $197.0M | $205.4M | $140.4M |
| Pre-Tax Income | $4.6M | $84.1M | $116.0M | $171.4M | $189.8M | $123.6M |
| Income Tax | $3.5M | $20.6M | $23.5M | $31.8M | $29.7M | $25.5M |
| Net Income | $1.4M | $62.1M | $91.4M | $137.5M | $159.5M | $98.1M |
| Diluted EPS | $0.03 | $1.25 | $1.74 | $2.60 | $3.06 | $2.03 |
Amphastar Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $191.8M | $183.1M | $171.2M | $183.9M |
| Net Income | $17.4M | $24.4M | $6.4M | $30.3M |
| Diluted EPS | $0.37 | $0.51 | $0.14 | $0.67 |
Amphastar Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $92.6M | $126.4M | $156.1M | $144.3M | $151.6M | $170.2M |
| Current Assets | $279.7M | $318.1M | $378.3M | $489.6M | $534.1M | $636.0M |
| Total Assets | $631.2M | $671.5M | $742.0M | $1.51B | $1.58B | $1.63B |
| Current Liabilities | $112.2M | $103.8M | $94.9M | $225.4M | $173.8M | $158.2M |
| Total Long-Term Debt | $58.2M | $80.4M | $79.7M | $603.6M | $613.8M | $621.3M |
| Total Liabilities | $182.5M | $226.0M | $213.3M | $873.5M | $845.2M | $840.5M |
| Shareholders' Equity | $402.3M | $445.5M | $528.7M | $639.4M | $732.3M | $788.8M |
Amphastar Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $57.3M | $98.0M | $89.2M | $183.5M | $213.4M | $156.1M |
| Cash From Investing | -$36.4M | -$28.7M | -$32.8M | -$649.1M | -$124.9M | -$70.3M |
| Cash From Financing | -$2.2M | -$37.0M | -$26.4M | $454.1M | -$81.0M | -$67.4M |
| Free Cash Flow | $23.4M | $70.5M | $65.1M | $145.3M | $172.3M | $121.2M |
Figures from Amphastar Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Amphastar Pharmaceuticals financials page for every line item.
Amphastar Pharmaceuticals Company Profile
| Ticker | AMPH |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Rancho Cucamonga, California |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001297184 |
Frequently Asked Questions
What was Amphastar Pharmaceuticals' revenue in fiscal 2025?
Amphastar Pharmaceuticals (AMPH) reported revenue of $719.9M for fiscal 2025.
What is Amphastar Pharmaceuticals' annual revenue history?
Amphastar Pharmaceuticals' annual revenue by fiscal year: 2020: $349.8M; 2021: $437.8M; 2022: $499.0M; 2023: $644.4M; 2024: $732.0M; 2025: $719.9M.
What was Amphastar Pharmaceuticals' net income in fiscal 2025?
Amphastar Pharmaceuticals reported net income of $98.1M for fiscal 2025.
What was Amphastar Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Amphastar Pharmaceuticals' diluted EPS was $2.03 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Amphastar Pharmaceuticals generate in fiscal 2025?
Amphastar Pharmaceuticals generated $121.2M of free cash flow in fiscal 2025.
What was Amphastar Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Amphastar Pharmaceuticals reported revenue of $183.9M.
How much debt does Amphastar Pharmaceuticals have?
Amphastar Pharmaceuticals reported $621.3M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Amphastar Pharmaceuticals are outstanding?
Amphastar Pharmaceuticals reported a weighted average of 43.6 million basic shares outstanding in 2026 Q2.
What is Amphastar Pharmaceuticals' market cap?
Based on its latest closing price, Amphastar Pharmaceuticals (AMPH) has a market capitalization of about $1.15B.
When does Amphastar Pharmaceuticals' fiscal year end?
Amphastar Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Amphastar Pharmaceuticals headquartered?
Amphastar Pharmaceuticals lists its business address in Rancho Cucamonga, California in its SEC filings.